Zelluna | Sustainability Performance
Ultimovacs ASA develops immunotherapy treatments aimed at providing solutions for cancer patients through innovative therapeutic approaches and clinical research.
1980
Norway
1,001 - 5,000 employees
Biotechnology
$500K - 1M in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#4000
Overallⓘ#116
in Norwayⓘ#63
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Energy consumption
Aligned
Controversy level
- Zelluna was a pre-revenue clinical-stage company with significant R&D costs and going-concern financing risks.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.